Mirabegron Not Linked to Higher Neoplasm Risk Than Antimuscarinics

A recent analysis indicates that mirabegron, a common treatment for overactive bladder (OAB), is not linked to a higher risk of neoplasms when compared to antimuscarinic therapies. While a short-term look at three years showed a modestly lower risk for those on mirabegron, that association vanished by the five-year mark and across the full follow-up period.

By showing no overall increase in cancer risk, the study provides a layer of stability for patients currently on the drug, though it stops short of declaring the medication “safe” in a definitive, long-term sense.

The Gap Between Short-Term Trends and Long-Term Data

The study utilized a multicenter target trial emulation to track how patients fared over time. The numbers shifted as the observation window widened. At the three-year mark, the composite hazard ratio was 0.924, suggesting a slight protective lean or lower risk for the mirabegron group. However, as the study pushed to five years, the hazard ratio moved to 0.975, effectively neutralizing the earlier finding.

To ensure these results weren’t just statistical noise, the investigators ran a “negative-control” analysis. They looked at Hodgkin lymphoma—a type of cancer that mirabegron isn’t expected to influence. When that analysis also showed no significant association, it reinforced the idea that the lack of neoplasm risk in the primary data was a genuine finding rather than a fluke of the study’s design.

But the data isn’t entirely clean. The researchers pointed to several gaps that prevent this from being a closed case, including a reliance on diagnostic codes rather than confirmed pathology reports and incomplete data regarding patient BMI and hemoglobin A1c levels.

A Concerning Signal in All-Cause Mortality

While the cancer data is reassuring, a different set of numbers warrants a closer look. Among patients who survived the first year of treatment and remained cancer-free, those who started mirabegron showed a higher risk of all-cause mortality, with a hazard ratio of 1.083.

The raw numbers tell a complex story: 5,059 deaths occurred in the mirabegron group compared to 6,816 in the antimuscarinic group. At first glance, that looks like mirabegron is safer. However, the antimuscarinic group had a significantly longer mean follow-up time—1,578 days compared to 1,229 days for the mirabegron group. When adjusted for time, the mortality signal for mirabegron becomes more prominent.

“The mortality signals alone should not prompt routine discontinuation or preferential antimuscarinic prescribing,” the investigators wrote.

The researchers suggest this spike might not be caused by the drug itself, but by “preferential prescribing.” Essentially, doctors may be giving mirabegron to patients who are already more vulnerable or frail—factors that are difficult to fully capture in a database, even when comorbidities are well-balanced.

The Stakes for Clinical Prescribing

Because the study found no overall neoplasm association, the authors explicitly state that increasing endoscopic screenings just because a patient is taking mirabegron is not justified by this evidence.

The decision of which drug to prescribe remains a delicate calculation. Antimuscarinics are known for cognitive vulnerabilities, particularly in elderly patients, while mirabegron’s profile involves different cardiovascular considerations. The study suggests that the choice should be driven by a patient’s specific symptom burden, their cardiovascular status, and their ability to afford the medication.

We have limited reassurance regarding cancer, but a lingering question regarding mortality. Until prospective confirmation and more detailed frailty assessments are completed, the medical community is unlikely to shift its standard of care.

The path forward relies on replication. The researchers noted that the study lacked an untreated comparator group, meaning we know how mirabegron compares to antimuscarinics, but not how either compares to doing nothing at all.

Worth a look